39795-63-6

Upstream product

• 15854-87-2 4-iodopyridine 
• 122775-35-3 3,4-Dimethoxyphenylboronic acid 
• 1120-87-2 4-bromopyridin 
• 895154-77-5 tris(3,4-dimethoxyphenyl)bismuthane 
• 19524-06-2 4-bromopyridine hydrochloride 
• 90684-19-8 4-(3'-methoxy-4'-hydroxyphenyl)-1,2,3,6-tetrahydropyridine 
• 94427-33-5 1-acetyl-4-(3'-methoxy-4'-acetoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 94427-38-0 1-acetyl-4-(3',4'-dimethoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 94427-34-6 1-acetyl-4-(3'-methoxy-4'-hydroxyphenyl)-1,2,3,6-tetrahydropyridine 
• 90-05-1 2-methoxy-phenol 
• 73390-11-1 4-piperidinone monohydrate 
• 626-61-9 4-Chloropyridine 
• 94427-39-1 4-(3',4'-dimethoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 110-86-1 pyridine 

Downstream Products

• 79445-42-4 4-(3',4'-dihydroxyphenyl)pyridine hydrobromide 

Relevant academic research and scientific papers

Programmable Self-Assembly of Heterometallic Palladium(II)–Copper(II) 1D Grid-Chain using Dinuclear Palladium(II) Corners with Pyrazole–Carboxylic Acid Ligands

A novel heterometallic diPdII–diCuII grid-chain, {[(bpy)4Pd4Cu2L4](NO3)4}n (2; bpy=2,2′-bipyridine), was synthesized through a programmable self-assembly approach from the molecular corners [(bpy)2Pd2(HL)(L)](NO3) (1) as linkers with CuII nitrate by using the bifunctional H2L ligand featuring primary (pyrazole) and secondary (benzoic acid) groups. Structural analysis revealed that 1D structure 2 consists of one [Cu2(O2CPh)4]n unit as a bridge and two [(bpy)2Pd2L2]n corners. Additionally, the catalytic effect of the heterometallic synergy on the Suzuki coupling reaction by using 2 was further explored.

Triarylbismuthanes as threefold aryl-transfer reagents in regioselective cross-coupling reactions with bromopyridines and quinolines

Cross-coupling studies using bromopyridines and bromoquinolines with triarylbismuths as threefold coupling reagents in substoichiometric amounts under Pd-catalysed conditions are disclosed. The reactivity was high with both mono- and dibromopyridyl substrates, and mono- and bis-couplings were carried out regioselectively. A library of monoaryl and diaryl pyridines was formed in high yields. A one-pot strategy provided a simple and straightforward synthesis of both symmetrical and unsymmetrical diarylpyridines. Arylations of 2-bromo- and 3-bromoquinolines were achieved with triarylbismuth reagents. This study demonstrates that triarylbismuths may be used as threefold arylating reagents for the synthesis of aryl pyridines and quinolines through couplings with bromopyridines and bromoquinolines under Pd-catalysed conditions. Copyright

Spin-crossover and liquid crystal properties in 2D cyanide-bridged Fe II-MI/II metalorganic frameworks

Novel two-dimensional heterometallic Fe(II)-M(NiII, Pd II, PtII, AgI, and AuI) cyanide-bridged metalorganic frameworks exhibiting spin-crossover and liquid crystal properties, formulated as {FeL2

The palladium catalysed Suzuki coupling of 2- and 4-chloropyridines

The Suzuki coupling of 2- and 4-chloropyridines with arylboronic acids is successfully performed under Pd(PPh3)4 catalysis. Moderate to good yields are obtained with 4-chloropyridines while 2-chloropyridines give excellent yields. The corresponding pyridine N-oxides react in the same manner. An easy and cheap access to arylpyridines, a class of compound with medicinal interest, is thus achieved.

Synthesis and Dihydropteridine Reductase Inhibitory Effects of Potential Metabolites of the Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a nigrostriatal neurotoxin which can cause irreversible parkinsonism in humans and primates by selective destruction of neurons in the substantia nigra.It is possible that MPTP could be metabolized by

4(or 3)-(3,4-Dihydroxyphenyl)pyridines, their cardiotonic use and cardiotonic use of their methyl ethers

4(or 3)-(3,4-Dihydroxyphenyl)pyridine, a cardiotonic agent, is prepared by demethylating 4(or 3)-(3,4-dimethoxyphenyl)pyridine, preferably by heating with aqueous hydrogen bromide. 4(or3)-[3,4-di-(OR)-phenyl]pyridine, where R is hydrogen or methyl, or pharmaceutically-acceptable acid-addition salt thereof is disclosed as the active component in a cardiotonic composition for increasing cardiac contractility and in the method for increasing cardiac contractility in a patient requiring such treatment. The novel isomeric 2-[3,4-di-(OR)-phenyl]pyridine, where R is hydrogen or methyl, is shown for comparative purposes.